23andMe and Genentech to Analyze Genomic Data for Parkinsonís Disease

Share

(January 16, 2015) - 23andMe, Inc., announced an agreement with Genentech, to generate whole genome sequencing data for approximately 3,000 people in 23andMe's Parkinson's disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson's disease. Read more…

Click for a printer friendly version

Back to top